AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: Johnson

DARZALEX® (daratumumab) reçoit le premier avis favorable du CHMP pour les patients atteints d’un myélome multiple indolent à haut risque

En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie1

Questex’s Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma’s Future Takes Shape

Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education

IMBRUVICA® (ibrutinib) reçoit un avis favorable du CHMP pour le traitement des patients atteints d’un lymphome à cellules du manteau (LCM) non préalablement traités...

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC1,2

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Emollient Market worth $4.08 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 23, 2025 /PRNewswire/ -- The report "Emollient Market by Type (Esters, Fatty Alcohols, Fatty Acids, Ethers, Silicones, and Other Types), Form...

Emollient Market worth $4.08 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 23, 2025 /PRNewswire/ -- The report "Emollient Market by Type (Esters, Fatty Alcohols, Fatty Acids, Ethers, Silicones, and Other Types), Form...

NICKELODEON KIDS’ CHOICE AWARDS 2025 HIGHLIGHTS AND WINNERS

Share It: @Nickelodeon @KidsChoiceAwards #KCA ** Click HERE to access interviews, clips, photos and footage from the show. HOLLYWOOD, Calif., June 21, 2025 /PRNewswire/ -- Nickelodeon Kids' Choice...

Johnson Pope Expands Legal Talent with the Addition of Jessica Warwick and Samuel C. Craig to Its St. Petersburg Office

ST. PETERSBURG, Fla., June 20, 2025 /PRNewswire/ -- Johnson, Pope, Bokor, Ruppel & Burns, LLP is proud to announce the addition of two new associate...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsJohnson